MyoKardia Buyout: BMS expands its cardiovascular portfolio for USD 13.1 Billion Bristol Myers Squibb has bounty years in a go with its shares skyrocketing as it decides to go on an acquisition spree. BMS has announced to acquire MyoKardia, a pharmaceutical company leveraging precision medicine to ...Find More
Samsung Biologics strikes a USD 330.8 Mn supply deal with AstraZeneca Samsung Biologics announced the conclusion of a long-term supply deal with AstraZeneca worth USD 330.8 Million. AZ has made several headlines the past few months, forming a slew of deals to manufacture and supply its products. H...Find More
Cycle Pharmaceuticals Hauls In USD 25 Million In A Debt Financing Agreement Cycle Pharmaceuticals, a biotech company focusing exclusively on rare diseases, announced a strategic financing agreement worth USD25 million credit facility with Deutsche Bank AG. Headquartered in the UK, Cycle Pharmaceut...Find More
Wave Life Sciences has recently announced the discontinuation of its drug suvodirsen, for the treatment of a rare Duchenne Muscular Dystrophy mutation. Duchenne Muscular Dystrophy is a progressive worsening of the skeletal and heart muscles resulting in weakness. The disorder, is due to deficient prot...Find More
Amgen has announced to purchase 20.5% of the stake in Chinese-American drug company BeiGene. As per the deal signed, Amgen will develop and commercialize around two dozen of its on-market as well as experimental drug compounds for the treatment of cancer in China. The shares purchased are worth USD 2.7 bill...Find More
AstraZeneca recently has announced the results of the clinical trials POSEIDON which included the study of a combination of drugs Imfinzi (durvalumab) and tremelimumab with chemotherapy in lung cancer. Imfinzi is a human monoclonal antibody which blocks the interaction of PD-L1 with PD-1 by binding itself with ...Find More
The US FDA today has given its nod to Trikafta (elexacaftor/ivacaftor/tezacaftor) of Vertex Pharmaceuticals, the first of its kind triple combination therapy for the patients with cystic fibrosis. The drug, Trikafta, has been approved for patients of age 12 years and older who have at least one F508del mutation...Find More
EicOsis has received USD 15Million grant from the National Institute of Drug Abuse (NIDA) to fund the clinical trials of non-opioid pain therapy. NIDA, with an aim to supplement NIH’s initiative Helping to End Addiction Long-Term (HEAL Initiative), has awarded the grant to the company. Deaths due to drug ov...Find More
ImaginAb has collaborated with AstraZeneca, Pfizer and Takeda to develop technology to facilitate tumour imaging and monitoring inside the cells. ImaginAb is an emerging imaging company focused on immune-oncology. The technology also helps in targeting and visualizing CD8+ T cells, which are activated by the im...Find More
The US FDA has approved Rybelsus (semaglutide) oral tablets to improve blood sugar in adult patients with Type II Diabetes. Rybelsus is an oral glucagon-like peptide (GLP-1) receptor protein treatment which has been approved after 15 years of the approval first GLP-1 agonist. GLP-1 is a hormone found in insuffi...Find More
Hear from our subject-matter experts and in-house KOL’s on Pharma and Healthcare market trends.
The American Society of Clinical Oncology is a platform that provides a global connection to researchers, pharma companies, and healthcare professions standing against cancer, finding a cure for it.